Equities research analysts predict that LivaNova PLC (NASDAQ:LIVN) will announce earnings of $0.91 per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for LivaNova’s earnings. The lowest EPS estimate is $0.88 and the highest is $0.93. LivaNova posted earnings of $1.01 per share during the same quarter last year, which indicates a negative year over year growth rate of 9.9%. The business is scheduled to announce its next quarterly earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that LivaNova will report full-year earnings of $3.58 per share for the current fiscal year, with EPS estimates ranging from $3.57 to $3.60. For the next year, analysts forecast that the company will report earnings of $3.94 per share, with EPS estimates ranging from $3.89 to $4.00. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for LivaNova.
LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 2nd. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $250.40 million for the quarter, compared to the consensus estimate of $245.18 million. LivaNova had a positive return on equity of 9.23% and a negative net margin of 1.99%. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS.
LIVN has been the topic of several recent analyst reports. Canaccord Genuity lifted their target price on LivaNova from $76.00 to $81.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $104.00 target price (up previously from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. BidaskClub downgraded LivaNova from a “buy” rating to a “hold” rating in a research note on Saturday, March 10th. Zacks Investment Research raised LivaNova from a “sell” rating to a “hold” rating in a research note on Tuesday, March 27th. Finally, ValuEngine raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $85.88.
Shares of LivaNova opened at $101.15 on Friday, Marketbeat.com reports. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of 29.64, a price-to-earnings-growth ratio of 3.06 and a beta of 0.76. LivaNova has a 1-year low of $59.12 and a 1-year high of $105.90.
In other news, Director Alfred J. Novak sold 1,000 shares of LivaNova stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $84.02, for a total transaction of $84,020.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction on Monday, April 16th. The shares were sold at an average price of $86.81, for a total value of $130,215.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,072 shares of company stock worth $2,542,618. 0.41% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Advisors Preferred LLC acquired a new position in shares of LivaNova during the 1st quarter valued at $113,000. Cubist Systematic Strategies LLC acquired a new position in shares of LivaNova during the 1st quarter valued at $174,000. QS Investors LLC grew its holdings in shares of LivaNova by 27,255.6% in the 4th quarter. QS Investors LLC now owns 2,462 shares of the company’s stock worth $197,000 after acquiring an additional 2,453 shares during the last quarter. Rehmann Capital Advisory Group acquired a new position in shares of LivaNova in the 4th quarter worth $216,000. Finally, Macquarie Group Ltd. grew its holdings in shares of LivaNova by 100.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,800 shares of the company’s stock worth $224,000 after acquiring an additional 1,400 shares during the last quarter. Institutional investors own 84.62% of the company’s stock.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.